DEAD-box helicase DP103 defines metastatic potential of human breast cancers

Journal of Clinical Investigation

Volumn 124, Issue 9, 2014, Pages 3807-3824

  Shin, Eun Myoung ^a,b,c   Hay, Hui Sin ^a,b,c   Lee, Moon Hee ^d   Goh, Jen Nee ^a,c   Tan, Tuan Zea ^a   Sen, Yin Ping ^c   Lim, See Wee ^c   Yousef, Einas M ^e   Ong, Hooi Tin ^f   Thike, Aye Aye ^g   Kong, Xiangjun ^h   Wu, Zhengsheng ^h   Mendoz, Earnest ⁱ   Sun, Wei ⁱ   Salto Tellez, Manuel ^a,c,j   Lim, Chwee Teck ^i,k,l   Lobie, Peter E ^a,c,m   Lim, Yoon Pin ^c   Yap, Celestial T ^c,n   Zeng, Qi ^b,c   Sethi, Gautam ^a,c   Lee, Martin B ^o   Tan, Patrick ^a,p,q   Goh, Boon Cher ^a,n,o   Miller, Lance D ^r   Thiery, Jean Paul ^a,b,c,n   Zhu, Tao ^h   Gaboury, Louis ^e   Tan, Puay Hoon ^g   Hui, Kam Man ^f   Yip, George Wai Cheong ^c   Miyamoto, Shigeki ^d   Kumar, Alan Prem ^a,c,n,s,t   Tergaonkar, Vinay ^b,c   more..

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^f DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^g SINGAPORE GENERAL HOSPITAL   (Singapore)

^h UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^k NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^l NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^m UNIVERSITY OF AUCKLAND   (New Zealand)

ⁿ Singapore Cancer Institute   (Singapore)

^o NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^p DUKE NUS MEDICAL SCHOOL   (Singapore)

^q GENOME INSTITUTE OF SINGAPORE   (Singapore)

^r WAKE FOREST SCHOOL OF MEDICINE   (United States)

^s CURTIN UNIVERSITY   (Australia)

^t UNIVERSITY OF NORTH TEXAS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEAD BOX PROTEIN 20; GELATINASE B; I KAPPA B KINASE; I KAPPA B KINASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR MARKER; UNCLASSIFIED DRUG; DDX20 PROTEIN, HUMAN; IKK2 PROTEIN, HUMAN; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MMP9 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR INVASION; BREAST TUMOR; CELL MOTION; GENETICS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DEAD BOX PROTEIN 20; FEMALE; HUMANS; I-KAPPA B KINASE; MAP KINASE KINASE KINASES; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B;

EID: 84907014874     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI73451     Document Type: Article

References (100)

1. Vernon AE, Bakewell SJ, Chodosh LA. Deciphering the molecular basis of breast cancer metastasis with mouse models. Rev Endocr Metab Disord. 2007;8(3):199-213.
2. Guo BH, et al. Bmi-1 promotes invasion and metastasis, and its elevated expression is correlated with an advanced stage of breast cancer. Mol Cancer. 2011;10(1):10.
3. Tavazoie SF, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147-152.
4. Yao ES, et al. Increased β1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007;67(2):659-664.
5. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591-602.
6. Zani S, Clary BM. A role for hepatic metastasectomy in stage IV melanoma and breast cancer: reestablishing the surgical modality. Oncology (Williston Park). 2011;25(12):1158-1164.
7. DeSantis C, Siegel R, Bandi P, Jemal A. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409-418.
8. Forouzanfar MH, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378(9801):1461-1484.
9. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer. 2003;3(1):55-63.
10. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559-1564.
11. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell. 2006;127(4):679-695.
12. Mego M, Mani SA, Cristofanilli M. Molecular mechanisms of metastasis in breast cancer - clinical applications. Nat Rev Clin Oncol. 2010;7(12):693-701.
13. Onishi T, Hayashi N, Theriault RL, Hortobagyi GN, Ueno NT. Future directions of bone-targeted therapy for metastatic breast cancer. Nat Rev Clin Oncol. 2010;7(11):641-651.
14. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(4):210-221.
15. Kraljevic Pavelic S, Sedic M, Bosnjak H, Spaventi S, Pavelic K. Metastasis: new perspectives on an old problem. Mol Cancer. 2011;10:22.
16. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000; 36(13 spec no):1621-1630.
17. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41(2):271-290.
18. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-174.
19. Meyer T, Hart IR. Mechanisms of tumour metastasis. Eur J Cancer. 1998;34(2):214-221.
20. Linder P. Dead-box proteins: a family affair - active and passive players in RNP-remodeling. Nucleic Acids Res. 2006;34(15):4168-4180.
21. Mouillet JF, et al. DEAD-box protein-103 (DP103, Ddx20) is essential for early embryonic development and modulates ovarian morphology and function. Endocrinology. 2008;149(5):2168-2175.
22. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res. 2006;34(15):4206-4215.
23. Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, Ingraham HA. The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol. 2005;25(5):1879-1890.
24. Ou Q, Mouillet JF, Yan X, Dorn C, Crawford PA, Sadovsky Y. The DEAD box protein DP103 is a regulator of steroidogenic factor-1. Mol Endocrinol. 2001;15(1):69-79.
25. Yan X, Mouillet JF, Ou Q, Sadovsky Y. A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity. Mol Cell Biol. 2003;23(1):414-423.
26. Klappacher GW, et al. An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell. 2002;109(2):169-180.
27. Charroux B, Pellizzoni L, Perkinson RA, Shevchenko A, Mann M, Dreyfuss G. Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems. J Cell Biol. 1999;147(6):1181-1194.
28. Grundhoff AT, et al. Characterization of DP103, a novel DEAD box protein that binds to the Epstein- Barr virus nuclear proteins EBNA2 and EBNA3C. J Biol Chem. 1999;274(27):19136-19144.
29. Meister G, Buhler D, Laggerbauer B, Zobawa M, Lottspeich F, Fischer U. Characterization of a nuclear 20S complex containing the survival of motor neurons (SMN) protein and a specific subset of spliceosomal Sm proteins. Hum Mol Genet. 2000;9(13):1977-1986.
30. Shpargel KB, Matera AG. Gemin proteins are required for efficient assembly of Sm-class ribonucleoproteins. Proc Natl Acad Sci U S A. 2005;102(48):17372-17377.
31. Gillian AL, Svaren J. The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20. J Biol Chem. 2004;279(10):9056-9063.
32. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18(18):2195-2224.
33. Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S. Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 1995;9(22):2723-2735.
34. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49-62.
35. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature. 2009;458(7237):430-437.
36. Teo H, et al. Telomere-independent Rap1 is an IKK adaptor and regulates NF-κB-dependent gene expression. Nat Cell Biol. 2010;12(8):758-767.
37. Wu ZH, et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell. 2010;40(1):75-86.
38. Staudt LM. Oncogenic activation of NF-κB. Cold Spring Harb Perspect Biol. 2010;2(6):a000109.
39. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol. 2011;12(8):715-723.
40. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell. 2002;109(suppl):S81-S96.
41. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H. Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene. 2002;21(13):2066-2078.
42. Nakshatri H, Goulet RJ, Goulet RJ Jr. NF- κB and breast cancer. Curr Probl Cancer. 2002;26(5):282-309.
43. Romieu-Mourez R, et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol. 2003;23(16):5738-5754.
44. Perkins ND. The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer. 2012;12(2):121-132.
45. Sovak MA, et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest. 1997;100(12):2952-2960.
46. Miyamoto S. Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. Cell Res. 2011;21(1):116-130.
47. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene. 2011;30(14):1615-1630.
48. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817-6830.
49. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006;13(5):738-747.
50. Biswas SK, Tergaonkar V. Myeloid differentiation factor 88-independent Toll-like receptor pathway: sustaining inflammation or promoting tolerance? Int J Biochem Cell Biol. 2007;39(9):1582-1592.
51. Rajendran P, et al. Celastrol suppresses growth and induces apoptosis of human hepatocellular carcinoma through the modulation of STAT3/JAK2 signaling cascade in vitro and in vivo. Cancer Prev Res (Phila). 2012;5(4):631-643.
52. Dey A, Wong E, Kua N, Teo HL, Tergaonkar V, Lane D. Hexamethylene bisacetamide (HMBA) simultaneously targets AKT and MAPK pathway and represses NFκB activity: implications for cancer therapy. Cell Cycle. 2008;7(23):3759-3767.
53. Irelan JT, et al. A role for IκB kinase 2 in bipolar spindle assembly. Proc Natl Acad Sci U S A. 2007;104(43):16940-16945.
54. Ang HL, Tergaonkar V. Notch and NFκB signaling pathways: do they collaborate in normal vertebrate brain development and function? Bioessays. 2007;29(10):1039-1047.
55. Cildir G, Akincilar SC, Tergaonkar V. Chronic adipose tissue inflammation: all immune cells on the stage. Trends Mol Med. 2013;19(8):487-500.
56. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441(7092):431-436.
57. Ghobrial IM, et al. Proteomic analysis of mantlecell lymphoma by protein microarray. Blood. 2005;105(9):3722-3730.
58. Verhaak RG, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110.
59. Prat A, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68.
60. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996;148(1):313-319.
61. Choong LY, Lim S, Chong PK, Wong CY, Shah N, Lim YP. Proteome-wide profiling of the MCF10AT breast cancer progression model. PLoS One. 2010;5(6):e11030.
62. Choong LY, et al. Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation. Genes Chromosomes Cancer. 2011;50(10):837-847.
63. Chan PK, Mak MS, inventors; Pacific Arrow Limited, assignee. Blocking the migration or metastasis of cancer cells by affecting adhesion proteins the uses of new compounds thereof. US patent application 20,100,004,190. January 7, 2010.
64. Zucchi I, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci U S A. 2004;101(52):18147-18152.
65. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
66. Liu Z, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270.
67. Mitra RS, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 2008;68(10):3959-3969.
68. Sakata K, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer. 2004;100(2):356-365.
69. Beliveau A, et al. Raf-induced MMP9 disrupts tissue architecture of human breast cells in threedimensional culture and is necessary for tumor growth in vivo. Genes Dev. 2010;24(24):2800-2811.
70. Nair RR, et al. A novel high-throughput screening system identifies a small molecule repressive for matrix metalloproteinase-9 expression. Mol Pharmacol. 2008;73(3):919-929.
71. Milde-Langosch K, et al. The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat. 2004;86(2):139-152.
72. Adamson R, Logan M, Kinnaird J, Langsley G, Hall R. Loss of matrix metalloproteinase 9 activity in Theileria annulata-attenuated cells is at the transcriptional level and is associated with differentially expressed AP-1 species. Mol Biochem Parasitol. 2000;106(1):51-61.
73. Chou YC, et al. Nuclear-targeted inhibition of NF-κB on MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells. Chem Biol Interact. 2010;184(3):403-412.
74. Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. bcl-2 over-expression enhances NF-κB activity and induces mmp-9 transcription in human MCF7(ADR) breastcancer cells. Int J Cancer. 2000;86(2):188-196.
75. Martinez N, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther. 2005;4(5):814-823.
76. Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell. 2003;115(5):565-576.
77. Mabb AM, Wuerzberger-Davis SM, Miyamoto S. PIASy mediates NEMO sumoylation and NF-κB activation in response to genotoxic stress. Nat Cell Biol. 2006;8(9):986-993.
78. Lee MH, Mabb AM, Gill GB, Yeh ET, Miyamoto S. NF-κB induction of the SUMO protease SENP2: a negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell. 2011;43(2):180-191.
79. Ghosh A, et al. Telomerase directly regulates NF-κB-dependent transcription. Nat Cell Biol. 2012;14(12):1270-1281.
80. Richter L, Bone JR, Kuroda MI. RNA-dependent association of the Drosophila maleless protein with the male X chromosome. Genes Cells. 1996;1(3):325-336.
81. Haas TL, et al. Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell. 2009;36(5):831-844.
82. Hoeller D, Hecker CM, Dikic I. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer. 2006;6(10):776-788.
83. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol. 2005;7(8):758-765.
84. Chen ZJ. Ubiquitination in signaling to and activation of IKK. Immunol Rev. 2012;246(1):95-106.
85. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643-658.
86. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle. 2006;5(9):1001-1007.
87. Tanaka K, Kawaguchi H, Nakamura Y, Taguchi K, Nishiyama K, Ohno S. Effect of HER2 status on risk of recurrence in women with small, node-negative breast tumours. Br J Surg. 2011;98(11):1561-1565.
88. Wu ZH, Miyamoto S. Induction of a pro-apoptotic ATM-NF-κB pathway and its repression by ATR in response to replication stress. EMBO J. 2008;27(14):1963-1973.
89. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426-434.
90. Stuelten CH, DaCosta Byfield S, Arany PR, Karpova TS, Stetler-Stevenson WG, Roberts AB. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β. J Cell Sci. 2005;118(pt 10):2143-2153.
91. Qian P, et al. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 2011;71(20):6463-6474.
92. Pandey V, et al. Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24. Transl Oncol. 2010;3(4):218-229.
93. Miller LD, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71(21):6728-6737.
94. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-210.
95. Pawitan Y, et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005;7(6):R953-R964.
96. Loi S, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239-1246.
97. Loi S, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics. 2008;9:239.
98. Miller LD, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005;102(38):13550-13555.
99. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
100. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118-127.